FDA Clears IND Application for New Gene Therapy – Rare Disease Report
Rare Disease Report |
FDA Clears IND Application for New Gene Therapy
Rare Disease Report Mathew Shanley. This morning, it was announced by Ultragenyx Pharmaceutical Inc. that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for DTX401 for the treatment of glycogen storage disease type … Ultragenyx Pharma (RARE) Reports Filing, FDA Clearance of IND for DTX401, Gene Therapy for Treatment of … Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene … FDA on board with start of clinical development of UltraGenyx's DTX401 for glycogen storage disorder |
